Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™

Published Online: Friday, June 1, 2012
This product bulletin was brought to you by Daiichi Sankyo, Inc.

This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.

To view the  Welchol® (colesevelam HCl) product information, please click here

To view the full product bulletin, please click here or the image below.



Related Articles
Here are new drugs for 2015 that pharmacists can expect to handle.
John Moorman, PharmD, BCPS, talks about changes in pharmacy practice to improve patient adherence to diabetes drugs as they move through transitions of care settings.
Pharmacists included in primary care teams improve antihypertensive medication management for patients with type 2 diabetes.
Women with diabetes have a considerably higher risk of developing coronary heart disease than men with diabetes.
Latest Issues
$auto_registration$